Serum thiobarbituric acid-reactive substances and free thiol levels in schizophrenia patients: Effects of antipsychotic drugs

Psychiatry Research

Volumn 177, Issue 1-2, 2010, Pages 18-21

  Huang, Tiao Lai ^a   Liou, Chia Wei ^a   Lin, Tsu Kung ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Antipsychotic drugs; Oxidative stress; Schizophrenia; TBARS; Thiols

Indexed keywords

BIOLOGICAL MARKER; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SULFHYDRYL COMPOUNDS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; YOUNG ADULT;

EID: 77952430708     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2009.01.017     Document Type: Article

References (39)

1. Akyol Ö., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S., Ozyurt H., Savaş H.A. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the possible role of oxidant/antioxidant imbalance. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2002, 26:995-1005.
2. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry 2003, 53:56-64.
3. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Judd F., Katz F., Katz P., Ording-Jespersen S., Little J., Conus P., Cuenod M., Do K.Q., Bush A.I. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biological Psychiatry 2008, 64:361-368.
4. Bindoli A., Rigobello M.P., Cavallini L., Dalla Libera A., Galizigna L. Decrease of serum malondialdehyde in patients treated with chlorpromazine. Clinica Chimica Acta 1987, 169:329-332.
5. Castagné V., Rougemont M., Cuenod M., Do K.Q. Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiology of Disease 2004, 15:93-105.
6. Chong M.Y., Wilkinson G. Validation of 30- and 12- item versions of the Chinese Health Questionnaire (CHQ) in patients admitted for general health screening. Psychological Medicine 1989, 19:495-505.
7. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209.
8. Dietrich-Muszalska A., Olas B., Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005, 16:386-391.
9. Do K.Q., Trabesinger A.H., Kirsten-Kru{double acute}ger M., Lauer C.J., Dydak U., Hell D., Holsboer F., Boesiger P., Cuénod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. The European Journal of Neuroscience 2000, 12:3721-3728.
10. Ellman G., Lysko H. A precise method for the determination of whole blood and plasma sulfhydryl groups. Analytical Biochemistry 1979, 93:98-102.
11. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV) 1997, American Psychiatric Press, Washington, DC.
12. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., Belmonte-de-Abreu P.S. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Progress In Neuro-Psychopharmacology & Biological Psychiatry 2006, 30:512-515.
13. Grignon S., Chianetta J.M. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Progress In Neuro-Psychopharmacology & Biological Psychiatry 2007, 31:365-369.
14. Grima G., Benz B., Parpura V., Cuénod M., Do K.Q. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophrenia Research 2003, 62:213-224.
15. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., Deppen P., Preisig M., Ruiz V., Steullet P., Tosic M., Werge T., Cuénod M., Do K.Q. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proceedings of the National Academy of Sciences of the United States of America 2007, 16(104):16621-16626.
16. Haidemenos A., Kontis D., Gazi A., Kallai E., Allin M., Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Progress In Neuro-Psychopharmacology & Biological Psychiatry 2007, 15:1289-1296.
17. Huang T.L. Decreased serum albumin levels in Taiwanese patients with schizophrenia. Psychiatry and Clinical Neuroscience 2002, 56:627-630.
18. Jacobsen J.P.R., Rodriguiz R.M., Mork A., Wetsel W.C. Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia. Neuroscience 2005, 132:1055-1072.
19. Karatas F., Karatepe M., Baysar A. Determination of free malondialdehyde in human serum by high-performance liquid chromatography. Analytical Biochemistry 2002, 311:76-79.
20. Kay S.R., Opler L.A., Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenia. Psychiatry Research 1988, 23:99-110.
21. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acid and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research 2002, 58:1-10.
22. Kropp S., Kern V., Lange K., Degner D., Hajak G., Kornhuber J., Rüther E., Emrich H.M., Schneider U., Bleich S. Oxidative stress during treatment with first- and second-generation antipsychotics. The Journal of Neuropsychiatry and Clinical Neurosciences 2005, 17:227-231.
23. Mahadik S.P., Pillai A., Joshi S., Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. International Review of Psychiatry 2006, 18:119-131.
24. Medina-Hernández V., Ramos-Loyo J., Luquin S., Sanchez L.F., Garcia-Estrada J., Navarro-Ruiz A. Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics. Journal of Psychiatric Research 2007, 41:652-658.
25. Mukherjee S., Mahadik S.P., Scheffer R., Correnti E.E., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophrenia Research 1996, 19:19-26.
26. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry 1979, 95:351-358.
27. Parikh V., Khan M.M., Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research 2003, 37:43-51.
28. 3K-ATPase and lipid peroxides in schizophrenia. Progress In Neuro-Psychopharmacology & Biological Psychiatry 2003, 27:431-440.
29. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., Wagh U.V., Debsikdar V.B., Mahadik S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research 2003, 121:109-122.
30. Reinke A., Martins M.R., Lima M.S., Moreira J.C., Dal-Pizzol F., Quevedo J. Halpoperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neuroscience Letters 2004, 372:157-160.
31. Sarandol A., Kirli S., Akkaya C., Altin A., Demirci M., Sarandol E. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2007, 31:1164-1169.
32. Scottish schizophrenia research group Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia. British Journal of Psychiatry 2000, 176:290-293.
33. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophrenia Research 1998, 32:1-8.
34. Yao J.K., Reddy R., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Research 2000, 97:137-151.
35. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15:287-310.
36. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Disease Markers 2006, 22:83-93.
37. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. The effect of Risperidone treatment on superoxide dismutase in schizophrenia. Journal of Clinical Psychopharmacology 2003, 23:128-131.
38. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Research 2006, 81:291-300.
39. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Haile C.N., Kosten T.A., Kosten T.R. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. Journal of Clinical Psychiatry 2007, 68:754-760.